Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (61-70 of 791) with videos related to

Pageof 80
Sort By:
Expert Opinion on Investigational Drugs|February 17, 2007
Clinical activity of tipifarnib in hematologic malignanciesElias Jabbour, Hagop Kantarjian, Jorge Cortes
Expert Opinion on Investigational Drugs|April 28, 2007
Dasatinib for the treatment of Philadelphia chromosome-positive leukaemiasElias Jabbour, Jorge Cortes, Hagop Kantarjian
Oncology (Williston Park, N.Y.)|June 15, 2007
Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?Elias Jabbour, Jorge Cortes, Hagop Kantarjian
Current Oncology Reports|June 14, 2021
Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid LeukemiaMahran Shoukier, Michal Kubiak, Jorge Cortes
Seminars in Hematology|November 26, 2002
Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndromeRazelle Kurzrock, Jorge Cortes, Hagop Kantarjian
Blood|September 21, 2004
Discontinuation of imatinib therapy after achieving a molecular responseJorge Cortes, Susan O'Brien, Hagop Kantarjian
Clinical Lymphoma & Myeloma|March 27, 2007
Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitorsEhab Atallah, Hagop Kantarjian, Jorge Cortes
Cancer|February 2, 2012
Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapyXuelin Huang, Jorge Cortes, Hagop Kantarjian
Expert Opinion on Pharmacotherapy|September 21, 2012
Dasatinib for the treatment of Philadelphia chromosome-positive leukemiasFabio P S Santos, Jorge Cortes
Blood|June 21, 2014
Clinical trials have a home in BloodJorge Cortes, Nancy Berliner, Bob Löwenberg
Pageof 80

Showing results (61-70 of 791) with videos related to

Sort By:
Pageof 80
Expert Opinion on Investigational Drugs|February 17, 2007
Clinical activity of tipifarnib in hematologic malignanciesElias Jabbour, Hagop Kantarjian, Jorge Cortes
Expert Opinion on Investigational Drugs|April 28, 2007
Dasatinib for the treatment of Philadelphia chromosome-positive leukaemiasElias Jabbour, Jorge Cortes, Hagop Kantarjian
Oncology (Williston Park, N.Y.)|June 15, 2007
Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?Elias Jabbour, Jorge Cortes, Hagop Kantarjian
Current Oncology Reports|June 14, 2021
Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid LeukemiaMahran Shoukier, Michal Kubiak, Jorge Cortes
Seminars in Hematology|November 26, 2002
Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndromeRazelle Kurzrock, Jorge Cortes, Hagop Kantarjian
Blood|September 21, 2004
Discontinuation of imatinib therapy after achieving a molecular responseJorge Cortes, Susan O'Brien, Hagop Kantarjian
Clinical Lymphoma & Myeloma|March 27, 2007
Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitorsEhab Atallah, Hagop Kantarjian, Jorge Cortes
Cancer|February 2, 2012
Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapyXuelin Huang, Jorge Cortes, Hagop Kantarjian
Expert Opinion on Pharmacotherapy|September 21, 2012
Dasatinib for the treatment of Philadelphia chromosome-positive leukemiasFabio P S Santos, Jorge Cortes
Blood|June 21, 2014
Clinical trials have a home in BloodJorge Cortes, Nancy Berliner, Bob Löwenberg
Pageof 80